Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...

Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

Ozempic and Wegovy, made by Novo, are on track to become the world’s top-selling drugs by 2025. Yet in 2024, ‘Wegovy Wednesday’ had already become one of the biggest weight-loss trends to sweep the ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...

Ozempic and Wegovy, used for diabetes and weight loss, show a link to NAION, a rare eye disorder causing blindness. A study ...